Poststroke Depressive Symptoms Are Associated With Increased Oxidative Deoxyribonucleic Acid Damage
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Poststroke depression is independently associated with poor health outcomes, such as increased mortality, disability, anxiety, and lower quality of life. Identifying the potential biomarkers and detailed mechanisms of poststroke depression may improve the effectiveness of therapeutic intervention. In this cross-sectional study, the authors recruited patients with subacute ischemic stroke who were consecutively admitted for neurorehabilitation. Depression was assessed with the Patient Health Questionnaire–9 (PHQ-9), with a cutoff based on a summed-items score of 10. Polysomnography and laboratory tests for oxidative stress and inflammation were arranged. In total, 139 patients (97 men [69.8%] and 42 women [30.2%]; mean age: 63.2 years [±13.4]) with recent ischemic stroke were recruited and divided into two groups based on their depressive symptoms. Body mass index (BMI), the Barthel Index, percentage of antidepressant usage, and percentage of rapid eye movement (REM) sleep differed significantly between the two groups. The PHQ-9 score was significantly correlated with the levels of total antioxidant capacity, C-reactive protein, and urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG). Urinary 8-OHdG, a marker of oxidative stress to DNA, remained significantly and positively correlated with PHQ-9 scores after adjusting for BMI, sleep-onset latency, Barthel Index, mean oxyhemoglobin saturation, age, antidepressant usage, and percentage of REM sleep by using multivariate linear regression. Depressive symptoms were related to increased oxidative DNA damage in patients with subacute ischemic stroke. Urinary 8-OHdG may serve as a potential biomarker for poststroke depression. Further longitudinal studies are needed to elucidate the causal relationship between poststroke depression and elevated oxidative stress level.
The estimated prevalence of depressive symptoms after a stroke is 31%.1 Recent studies have suggested that poststroke depression is independently associated with poor health outcomes such as increased mortality, disability, anxiety and lower quality of life.2 However, most of the traditional risk factors reported in the literature such as genetic factors, age, gender, and stroke severity are not amendable.3 Identifying the potential biomarkers and detailed mechanism of poststroke depression is the most important need for future study to improve the effectiveness of therapeutic intervention.3,4
Many studies support the role of inflammation in depression.5,6 However, studies regarding poststroke depression are far fewer and inconclusive. Some recent studies supported the role of proinflammatory cytokines in the pathogenesis of poststroke depression.7,8 Serum concentrations of interleukin-6 (IL-6) were linked with the apathetic-amotivational and somatic symptoms of depression in the acute phase of stroke.7 Conversely, Jiménez et al.9 studied patients with acute stroke and found no difference in C-reactive protein (CRP) or IL-6 in patients with or without poststroke depression. Ferrarese et al.10 even found that the CRP level decreased in patients with poststroke depression one month poststroke. Most of the studies regarding poststroke depression have been conducted in the acute phase of stroke. However, high levels of IL-6 have been found up to 1 month poststroke,11 and elevated levels of CRP may be induced by stroke itself and have been reported to be sustained up to three months after stroke.12
Therefore, those findings cannot be generalized to patients with stroke in the subacute or chronic phase.
Oxidative stress has been found to be involved in the pathophysiology of depression.13–15 Recent studies have found that total antioxidant capacity16 was decreased and that 8-hydroxy-2′-deoxyguanosine (8-OHdG),14 a modified DNA base that indicates oxidative DNA damage, was increased in patients with depression. Animal studies have also found that oxidative stress was involved in the pathophysiology of poststroke depression.17 However, few studies on the role of oxidative stress in the mechanisms of poststroke depression have yet been performed in clinical population, and the temporal profiles of elevated oxidative stress level due to acute stroke are currently unclear. Gu et al. recently found lower serum uric acid in the acute phase of stroke as a biological predictor of poststroke depression three months after stroke and speculated that defense against oxidative stress was a mechanism.18
The association between depression and obstructive sleep apnea is controversial. A recent systematic review and meta-analysis study suggested that treatment of obstructive sleep apnea might reduce depressive symptoms based on questionnaires in stroke-free patients.19 However, obstructive sleep apnea severity was not independently related to depression diagnosed by standardized psychiatric interview in patients with untreated obstructive sleep apnea.20 Moreover, neither the severity nor the existence of obstructive sleep apnea was related to depression questionnaire score in healthy elderly individuals.21 Similar to poststroke depression, obstructive sleep apnea is also very common in patients with stroke, with a prevalence rate exceeding 50%.22 However, few studies have been conducted focusing on the association between poststroke depression and obstructive sleep apnea in patients with stroke. Only two small studies reported improvement in depression following continuous positive airway pressure treatment for sleep-disordered breathing in patients with acute stroke.23,24 As those studies did not recruit patients without obstructive sleep apnea, they do not elucidate whether poststroke depression is independently associated with obstructive sleep apnea.
The primary goal of this study was to evaluate the association of poststroke depression with potentially correctable targets, including inflammation, oxidative stress, and obstructive sleep apnea in patients with subacute stroke.
Methods
Participants
This cross-sectional study recruited patients with subacute ischemic stroke who had been admitted consecutively for neurorehabilitation. Ischemic stroke was diagnosed based on neurological examination and image studies. Patients who met any of the following criteria were excluded: aphasia or severely decreased consciousness causing communication difficulty; unstable medical and neurological status such as active infection, delirium, or poor controlled diabetic mellitus; and advanced renal disease (chronic kidney disease, stage 3 or above) or history of central nervous system disease such as hemorrhage, Parkinson’s disease, or malignancy. Patients with central sleep apnea were also excluded. Drugs or food supplements, which may ameliorate inflammation or oxidative stress, were prohibited except medication prescribed by physicians.
The study was approved by the ethics committee of Chang Gung Memorial Hospital. All participants provided informed consent.
Clinical Evaluation
Comprehensive evaluations including demographic data and history of traditional vascular risk factors were performed during admission. The National Institutes of Health Stroke Scale (NIHSS)25 at stroke onset was obtained from relevant medical reports to represent initial stroke severity. Functional outcome was measured by using the Barthel Index.26
Depression was assessed by using the Patient Health Questionnaire–9 (PHQ-9), which is a self-reported measure of depression matching the DSM-IV criteria of major depression.27 A cutoff based on a summed-items score of 10 or above is recommended in screening for major depressive disorder.28 The diagnostic value of PHQ-9 scores ≥10 for poststroke depression was found to be good, with a sensitivity of 0.80 (95% [confidence interval] CI=0.62–0.98) and a specificity of 0.78 (95% CI=0.69–0.83).29
Depression may be defined by PHQ-9 scores ≥10 according to the literature, yet this study referred that patients with PHQ-9 scores ≥10 had depressive symptoms.
Polysomnography
Polysomnography was performed with an Embla N7000 (Somnologica, Reykjavik, Iceland) in the sleep center from 10:00 p.m. to 7:00 a.m. on the same day of Barthel Index and PHQ-9 evaluation.
The test comprised six electroencephalography (EEG) channels (F3-A1, F4-A2, C3-A1, C4-A2, O1-A1, and O2-A2), thoracic and abdominal movement sensors (inductance plethysmography), a chin and bilateral anterior tibial surface electromyogram, an oxyhemoglobin saturation detector (finger pulse oximetry), an electrocardiogram, an electro-oculogram, and nasal and oral airflow sensors (nasal pressure cannula and oronasal thermistor). Diagnosis was made by a board-certified sleep physician and was based primarily on the American Academy of Sleep Medicine Task Force recommendations:30 Severe obstructive sleep apnea was diagnosed when the apnea-hypopnea index was >30 events/hour−1 and >50% of respiratory events were of the obstructive or mixed type. A diagnosis of central sleep apnea was made when ≥50% of respiratory events were of the central type.
Inflammation and Oxidative Stress Biomarkers
Samples of peripheral venous blood and urine were taken at 7:00 a.m. after the polysomnography study. Blood was collected in lithium heparin PST II tubes and SST II Advance tubes (BD Vacutainer; Becton Dickinson, Heidelberg, Germany) and was centrifuged at 3,000 rpm for 10 minutes. Then, samples were immediately separated in aliquots and stored at −80°C until analysis in the Medical Center Laboratory. The total antioxidant capacity was determined on the Cobas Mira Plus (Roche Diagnostics, Mannheim, Germany) by the ferric reducing ability of plasma assay31 with intra- and interassay coefficients of variation of 2% and 5%, and 1% and 3%, respectively, at two levels. The urinary 8-OHdG was measured by microplate competitive enzyme-linked immunosorbent assay (ELISA)32 with intra- and interassay coefficients of variation of 5.9% and 8.0%, respectively. The level of urinary 8-OHdG excretion was then normalized by the urinary creatinine concentration and expressed as the urinary (8-OHdG [nanograms/milliliter]/creatinine [milligrams/milliliter]) ratio. Serum IL-6 was measured using ELISA kits (Quantikine HS IL-6 Immunoassay, #HS600B; R&D Systems, Minneapolis, MN) and quantified at 490 nm by a microplate reader (SpectraMax 190; Molecular Devices, Sunnyvale, Calif.), with a minimum detectable dose of 0.039 pg/ml and inter- and intra-assay coefficients of variation <10%. CRP was determined with a latex aggregation immunoassay (Nanopia CRP assay; Daiichi Pure Chemicals, Tokyo, Japan) using a Hitachi 7600-210 analyzer (Hitachi Instruments Engineering, Tokyo, Japan), which has a lower limit of sensitivity of 0.1 mg/l and inter- and intra-assay coefficients of variation ≤5%.
Statistical Analyses
Statistical analyses were performed using IBM SPSS Statistics software, version 20 (IBM Software Group; Chicago, IL). Continuous variables were assessed for normal distributions. Non-normally distributed variables were log-transformed (NIHSS, IL-6, and total cholesterol and high-density lipoprotein [HDL]) to achieve normality and then analyzed with parametric tests and presented as geometric means. Participants were stratified into depressive (PHQ-9 scores ≥10) and nondepressive (PHQ-9 scores <10) groups. Nominal variables were compared using a chi-square test. Continuous variables were compared using the Student’s t test or two-sample Kolmogorov–Smirnov test, on the basis of whether they were normally distributed. Univariate correlations between PHQ-9 score and continuous variables were determined with Spearman correlation analysis. Potential variables were selected if they were related to PHQ-9 scores at p<0.1 and then entered into the multivariate linear regression model to calculate the independent predictors for PHQ-9 score. Values of p<0.05 were considered significant.
Results
In total, 139 patients (97 men [69.8%] and 42 women [30.2%]; mean age, 63.2±13.4 years) with recent ischemic stroke were consecutively recruited. Table 1 shows the clinical characteristics and sleep parameters of the two groups. Time interval from stroke onset to the date of polysomnography study and parameters of obstructive sleep apnea, including apnea-hypopnea index and disturbance index, did not differ between the two groups (Table 1). BMI, stroke severity (NIHSS and Barthel Index), percentage of antidepressant (including tricyclic antidepressant, selective serotonin uptake inhibitor, and serotonin-norepinephrine reuptake inhibitor) usage, and percentage of rapid eye movement (REM) sleep differed significantly between the two groups (Table 1). Participants with hyperlipidemia were all on statin therapy for secondary stroke prevention. No participants with a diagnosis such as asthma, autoimmune disease, celiac disease, glomerulonephritis, or inflammatory bowel disease, which could profoundly affect the inflammatory status, were recruited in this study. Steroids, nonsteroidal anti-inflammatory drugs, and specific classes of drug with a main action on inflammation were not prescribed during the study period except aspirin. Sleep-onset latency, level of IL-6, and urinary 8-OHdG were marginally different between the two groups (Table 1). Table 2 presents the univariate correlation between PHQ-9 score and continuous variables. The PHQ-9 score was significantly correlated with the levels of total antioxidant capacity, Hs-CRP, and urinary 8-OHdG and was marginally significantly correlated with age and level of IL-6. However, the PHQ-9 score was not significantly correlated with major parameters of obstructive sleep apnea, such as apnea-hypopnea index score and desaturation index score.
| Characteristic | Depression (N=70) | No Depression (N=69) | p |
|---|---|---|---|
| Age (years)b | 65.8 (55.9–74.2) | 59.7 (53.6–72.1) | 0.280 |
| Female (N) | 22 (31.4%) | 20 (29.0%) | 0.754 |
| Body mass index (kg/m2) | 24.0 (3.6) | 25.2 (3.7) | 0.042* |
| Neck circumference (mm) | 381.9 (30.7) | 385.4 (39.1) | 0.556 |
| National Institutes of Health Stroke Scale (pt)c,d | 10.73 | 8.86 | <0.001** |
| Barthel Index at polysomnography (pt)b | 30.0 (15.0–45.0) | 45.0 (30.0–55.0) | 0.008** |
| Interval of polysomnography (months)b,e | 2.3 (1.2–4.1) | 2.2 (1.2–3.9) | 0.974 |
| Apnea-hypopnea index (events/hour)b | 38.1 (23–57.4) | 36.4 (16.5–51.5) | 0.583 |
| Disturbance index (events/hour)b | 31.1 (16.9–55.6) | 27.9 (9.8–47.9) | 0.163 |
| Total sleep time (minutes)b | 252.4 (212.0–300.2) | 267.0 (223.8–304.5) | 0.208 |
| Sleep-onset latency (minutes)b | 18.5 (10.0–34.5) | 13.8 (7.3–22.4) | 0.096 |
| Sleep efficiency (%)b | 72.6 (61.0–83.0) | 75.0 (64.8–85.9) | 0.308 |
| Deep sleep (%)b | 19.5 (11.7–26.1) | 17.0 (9.2–23.6) | 0.676 |
| Rapid eye movement (%) | 9.45 (7.45) | 12.2 (6.09) | 0.019* |
| Mean SpO2 (%) | 92.7 (91.2–94.5) | 93.1 (91.7–94.6) | 0.164 |
| Minimum SpO2 (%)b | 76.5 (63.8–83.0) | 779.0 (65.5– 85.5) | 0.393 |
| Epworth Sleepiness Scale (pt)b | 9.0 (5.8–12) | 8.0 (4.5–13.5) | 0.716 |
| Severe obstructive sleep apnea (N) | 43 (61.4%) | 43 (62.3%) | 0.914 |
| hs-CRP (mg/dL)b | 2.81 (1.16–5.7) | 1.91 (0.99–6.15) | 0.336 |
| Total antioxidant capacity (μmol/L) | 586.1 (107.7) | 607.1 (107.0) | 0.252 |
| Interleukin-6 (pg/mL)c | 3.14 | 2.32 | 0.062 |
| Urinary 8-OHdG (ng/mgCr)b | 40.1 (29.4–58.2) | 38.6 (30.6–47.2) | 0.056 |
| Total cholesterol (mg/dL)b | 174.6 | 164.8 | 0.182 |
| LDL (mg/dL)b | 108 (92–130) | 99.5 (78.3–138.8) | 0.119 |
| HDL (mg/dL)c | 40.2 | 39.1 | 0.544 |
| Smoking (N) | 30 (42.9%) | 33 (47.8%) | 0.556 |
| Hypertension (N) | 61 (87.1%) | 56 (81.2%) | 0.334 |
| Recurrent cerebrovascular accident (N) | 19 (27.1%) | 21 (30.4%) | 0.668 |
| Coronary artery disease (N) | 5 (7.1%) | 6 (8.7%) | 0.735 |
| Diabetes mellitus (N) | 29 (41.4%) | 32 (46.4%) | 0.557 |
| Hyperthyroidism (N) | 5 (7.1%) | 2 (2.9%) | 0.441 |
| Hyperlipidemia (N) | 60 (85.7%) | 57 (82.6%) | 0.616 |
| Hypertriglycemia (N) | 19 (29.2%) | 18 (26.1%) | 0.684 |
| Hyperuricemia (N) | 4 (5.9%) | 3 (4.5%) | 1.0 |
| Antidepressants (N) | 21 (30.0%) | 10 (14.5%) | 0.028* |
a
Values are means (SD), unless indicated otherwise. Statistically significant values are indicated in bold.
Abbreviations: HDL=high-density lipoprotein; hs-CRP=high-sensitivity C-reactive protein; LDL=low-density lipoprotein; pt=point; SpO2=oxyhemoglobin saturation by pulse oximetry; 8-OHdG=8-hydroxy-2′-deoxyguanosine.
b
Medium (interquartile range).
c
Geometric mean.
d
Data were unavailable for 24 patients with depression and 24 patients without depression, respectively.
e
Time interval from stroke onset to date of polysomnography.
*
p<0.05; **p<0.01.
| Item | Rho | p |
|---|---|---|
| Age (years) | 0.164 | 0.054 |
| National Institutes of Health Stroke Scale | 0.340 | 0.001** |
| Barthel Index | –0.395 | <0.001** |
| Body mass index (kg/m2) | 0.023 | 0.006** |
| Neck circumference | –0.051 | 0.548 |
| Apnea-hypopnea index | 0.084 | 0.324 |
| Desaturation index | 0.130 | 0.127 |
| Mean desaturation | 0.117 | 0.169 |
| Minimum SpO2 | –0.079 | 0.357 |
| Mean SpO2 | –0.172 | 0.043* |
| Total sleep time | –0.107 | 0.210 |
| Sleep-onset latency | 0.229 | 0.007** |
| Sleep efficiency (%) | –0.108 | 0.208 |
| Deep sleep (%) | 0.077 | 0.370 |
| Rapid eye movement (%) | –0.215 | 0.011* |
| Epworth Sleepiness Scale | –0.041 | 0.629 |
| Total cholesterol | 0.058 | 0.530 |
| Low-density lipoprotein | 0.068 | 0.457 |
| High-density lipoprotein | 0.067 | 0.474 |
| Total antioxidant capacity | –0.171 | 0.044* |
| Hs-CRP | 0.189 | 0.028* |
| Urinary 8-OHdG | 0.202 | 0.017* |
| Interleukin-6 | 0.174 | 0.070 |
a
Statistically significant values are indicated in bold. Abbreviations: Hs-CRP=high-sensitivity C-reactive protein; SpO2=oxyhemoglobin saturation by pulse oximetry; 8-OHdG=8-hydroxy-2′-deoxyguanosine.
*
p<0.05; **p<0.01.
Multivariate linear regression analyses were performed based on inflammation and oxidative stress biomarkers, together with other independent variables, including BMI, sleep-onset latency, Barthel Index score, mean SpO2 (oxyhemoglobin saturation by pulse oximetry), age, antidepressant usage, and percentage of REM sleep, to predict the PHQ-9 score. The BMI, sleep-onset latency, Barthel Index score, antidepressant usage, and urinary 8-OHdG remained significantly correlated with PHQ-9 score (R2=0.317, p<0.001) (Table 3). Levels of total antioxidant capacity, Hs-CRP, and IL-6 were not significantly associated with PHQ-9 score after adjusting for other independent variables.
| Variable | Standardized β | Unstandardized β | 95% CI | p |
|---|---|---|---|---|
| Body mass index (kg/m2) | –0.266 | –0.187 | –0.499 to –0.034 | 0.025* |
| Sleep-onset latency | 0.023 | 0.159 | 0.002 to 0.045 | 0.034* |
| Barthel Index | –0.069 | –0.259 | –0.111 to –0.027 | 0.002** |
| Mean SpO2 | –0.269 | –0.116 | –0.638 to 0.1 | 0.152 |
| Urinary 8-OHdG | 0.057 | 0.208 | 0.015 to 0.099 | 0.008** |
| Age (years) | –0.014 | –0.037 | –0.083 to 0.054 | 0.678 |
| Rapid eye movement (%) | –0.011 | –0.014 | –0.138 to 0.116 | 0.87 |
| Antidepressant use | 2.319 | 0.184 | 0.39 to 4.248 | 0.019* |
a
Statistically significant values are indicated in bold. Abbreviations: SpO2=oxyhemoglobin saturation by pulse oximetry; 8-OHdG=8-hydroxy-2′-deoxyguanosine. R=0.563, R2=0.317, F=7.527, df=8, 130, p<0.001.
*
p<0.05; **p<0.01.
Discussion
This study is the first to our knowledge to report the independent association between increased oxidative stress and severity of depressive symptoms in patients with subacute ischemic stroke after adjusting for potential risk factors. Therefore, intervention to reduce oxidative stress is a possible treatment option for depressive symptoms in patients with ischemic stroke.
The findings of independent and positive association between urinary 8-OHdG, one of the most robust biomarkers of oxidative stress, and depressive symptoms suggest that poststroke depressive symptoms are related to raised oxidative damage to DNA. These findings are in agreement with the result of a recent systematic review and meta-analysis study that 8-OHdG was increased in stroke-free patients with depression.14 The PHQ-9 score performs well as a continuous scale,27 but the best PHQ-9 cutoff scores for screening poststroke depression remain to be proved. The findings that PHQ-9 scores ≥10 did not provide the highest sensitivity and specificity for poststroke depression screening33 might be the reason why the differences in urinary 8-OHdG level between the two groups did not reach statistical significance. The concomitant raised in oxidative DNA damage and lack of an adequately corresponding total antioxidant capacity change suggest that the antioxidant/pro-oxidant balance is perturbed by the outweighing oxidative stress in patients with stroke who had severe depressive symptoms. Depression has been found to be linked with accelerated cellular aging reflected by telomere length shortening.34 As an elevated level of 8-OHdG was found to be a reliable biomarker of oxidative DNA damage in patients with chronic stroke35 and independently associated with telomere shortening in patients with diabetes,36 it is biologically plausible to suggest that the mechanism of the independent association between poststroke depressive symptoms and elevated level of urinary 8-OHdG may result from accelerated cellular aging. The independent association between urinary 8-OHdG and PHQ-9 score found in this study, together with the findings that lower levels of uric acid might predict poststroke depression18 and a phase 2 clinical trial in Parkinson’s disease that revealed a potential effect of increased uric acid on mood,37 suggests that raised oxidative stress might be a risk factor and a potentially treatable target for depressive symptoms in patients with ischemic stroke. As poststroke depression is a well-known predictor for poor recovery from stroke,3 this study explains why high urinary 8-OHdG has been reported to be a valid predictor of poor functional outcomes in patients with acute and chronic stroke.35,38
Inflammation is not independently associated with depressive symptoms in patients with subacute stroke. The main difference between this investigation and previous studies regarding the relationship between inflammation and poststroke depression is the timing after the index stroke when patients were recruited. The influence of acute ischemic stroke on early and sustained inflammatory response9,11 gradually attenuated in the subacute phase of stroke, reducing the bias in the association between inflammation and depressive symptoms in this study. Our results are also consistent with a meta-analysis study that did not find any association between poststroke depression and inflammatory biomarkers (CRP, IL-18, IL-6, and tumor necrosis factor α) in patients within a mean of five weeks poststroke.39 Although all recognized possible covariates were analyzed and adjusted by multivariate regression analyses, we could not exclude unknown sources of bias. This is particularly true, given that inflammatory biomarkers might be influenced by many comorbidities and medication in patients with stroke. Larger studies that measure more inflammatory biomarkers in patients with subacute or chronic stroke are needed to confirm these findings.
Neither the presence of severe obstructive sleep apnea nor the severity of obstructive sleep apnea is associated with depressive symptoms in patients with subacute stroke. Whether obstructive sleep apnea in the elderly individuals represents the same disease as that in the younger subjects remains inconclusive.40 As the mean age of 63.2 in this study is high, the analytical results support the findings of Sforza et al. that obstructive sleep apnea is not related to depression in healthy elderly individuals.21 Lavie et al. reported an unexpected survival advantage from sleep apnea in elderly individuals and speculated that elderly individuals with sleep apnea may be exceptionally resistant survivors who are exceptionally adapted to the resulting prolonged stress.41 Our previous findings that patients with ischemic stroke who have severe obstructive sleep apnea developed adaptive antioxidative response42 supported their theory and may explain why this study found no association between obstructive sleep apnea and poststroke depressive symptoms.
The high percentage of participants with depressive symptoms in this study is consistent with previous findings by Farner et al.43 and may be owing to the selection bias that participants admitting for inpatient rehabilitation generally suffered from moderate to severe stroke. Place of residence, living together or alone, and participating in active rehabilitation programs are factors reported to be associated with poststroke depression.44 As participants were admitted for neurorehabilitation, similar physical activities and living environment made these variables well controlled in this study.
This study has several limitations. First, this cross-sectional study cannot explain the causal relationship between oxidative DNA damage and depressive symptoms in patients with subacute ischemic stroke. Second, the selection bias exists; therefore, an extrapolation to all patients with ischemic stroke is not possible. Patients with ischemic stroke who also had severe depression, active psychiatric disorder, or neurological deficits of very mild or severe degree were excluded because they were not suitable for inpatient neurorehabilitation. Third, the analysis did not include prestroke history of psychiatric disorders or social–economic status.
Finally, the poststroke depressive symptoms were evaluated only by the PHQ-9, without further follow-up with a more detailed psychiatric assessment using the DSM-IV.
In conclusion, increased oxidative DNA damage is associated with depressive symptoms in patients with subacute ischemic stroke. Urinary 8-OHdG may serve as a potential biomarker for poststroke depression. Further longitudinal studies are indicated to elucidate the causal relationship between poststroke depression and the elevated oxidative stress level.
Acknowledgments
The authors thank Ted Knoy for his editorial assistance.
References
1.
Hackett ML, Pickles K: Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke 2014; 9:1017–1025
2.
Ayerbe L, Ayis S, Crichton S, et al: The long-term outcomes of depression up to 10 years after stroke; the South London Stroke Register. J Neurol Neurosurg Psychiatry 2014; 85:514–521
3.
Robinson RG, Jorge RE: Post-stroke depression: a review. Am J Psychiatry 2016; 173:221–231
4.
Pietra Pedroso VS, Rachid MA, Teixeira AL: Biomarkers in post-stroke depression. Curr Neurovasc Res 2016; 13:163–173
5.
Miller AH, Raison CL: The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16:22–34
6.
Spalletta G, Bossù P, Ciaramella A, et al: The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006; 11:984–991
7.
Spalletta G, Cravello L, Imperiale F, et al: Neuropsychiatric symptoms and interleukin-6 serum levels in acute stroke. J Neuropsychiatry Clin Neurosci 2013; 25:255–263
8.
Li W, Ling S, Yang Y, et al: Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuroendocrinol Lett 2014; 35:104–109
9.
Jiménez I, Sobrino T, Rodríguez-Yáñez M, et al: High serum levels of leptin are associated with post-stroke depression. Psychol Med 2009; 39:1201–1209
10.
Ferrarese C, Mascarucci P, Zoia C, et al: Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999; 19:1004–1009
11.
Zhan Y, Yang YT, You HM, et al: Plasma-based proteomics reveals lipid metabolic and immunoregulatory dysregulation in post-stroke depression. Eur Psychiatry 2014; 29:307–315
12.
Emsley HC, Smith CJ, Gavin CM, et al: An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003; 139:93–101
13.
Maes M, Galecki P, Chang YS, et al: A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:676–692
14.
Black CN, Bot M, Scheffer PG, et al: Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 2015; 51:164–175
15.
Mazereeuw G, Herrmann N, Andreazza AC, et al: A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatr Dis Treat 2015; 11:2479–2491
16.
Ghodake SR, Suryakar AN, Kulhalli PM, et al: A study of oxidative stress and influence of antioxidant vitamins supplementation in patients with major depression. Curr Neurobiol 2012; 3:107–111
17.
Di Lorenzo A, Nabavi SF, Sureda A, et al: Antidepressive-like effects and antioxidant activity of green tea and GABA green tea in a mouse model of post-stroke depression. Mol Nutr Food Res 2016; 60:566–579
18.
Gu Y, Han B, Wang L, et al: Low serum levels of uric acid are associated with development of poststroke depression. Medicine (Baltimore) 2015; 94:e1897
19.
Povitz M, Bolo CE, Heitman SJ, et al: Effect of treatment of obstructive sleep apnea on depressive symptoms: systematic review and meta-analysis. PLoS Med 2014; 11:e1001762
20.
Björnsdóttir E, Benediktsdóttir B, Pack AI, et al: The prevalence of depression among untreated obstructive sleep apnea patients using a standardized psychiatric interview. J Clin Sleep Med 2016; 12:105–112
21.
Sforza E, Saint Martin M, Barthélémy JC, et al: Mood disorders in healthy elderly with obstructive sleep apnea: a gender effect. Sleep Med 2016; 19:57–62
22.
Mohsenin V: Obstructive sleep apnea: a new preventive and therapeutic target for stroke: a new kid on the block. Am J Med 2015; 128:811–816
23.
Sandberg O, Franklin KA, Bucht G, et al: Nasal continuous positive airway pressure in stroke patients with sleep apnoea: a randomized treatment study. Eur Respir J 2001; 18:630–634
24.
Ryan CM, Bayley M, Green R, et al: Influence of continuous positive airway pressure on outcomes of rehabilitation in stroke patients with obstructive sleep apnea. Stroke 2011; 42:1062–1067
25.
Brott T, Adams HP Jr, Olinger CP, et al: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864–870
26.
Shah S, Vanclay F, Cooper B: Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 1989; 42:703–709
27.
Manea L, Gilbody S, McMillan D: A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry 2015; 37:67–75
28.
Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606–613
29.
de Man-van Ginkel JM, Hafsteinsdóttir T, Lindeman E, et al: An efficient way to detect poststroke depression by subsequent administration of a 9-item and a 2-item Patient Health Questionnaire. Stroke 2012; 43:854–856
30.
Berry RB, Budhiraja R, Gottlieb DJ, et al: Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. J Clin Sleep Med 2012; 8:597–619
31.
Benzie IF, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996; 239:70–76
32.
Chiou CC, Chang PY, Chan EC, et al: Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 2003; 334:87–94
33.
Turner A, Hambridge J, White J, et al: Depression screening in stroke: a comparison of alternative measures with the Structured Diagnostic Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (major depressive episode) as criterion standard. Stroke 2012; 43:1000–1005.
34.
Verhoeven JE, Révész D, Epel ES, et al: Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol Psychiatry 2014; 19:895–901
35.
Hsieh YW, Lin KC, Korivi M, et al: The reliability and predictive ability of a biomarker of oxidative DNA damage on functional outcomes after stroke rehabilitation. Int J Mol Sci 2014; 15:6504–6516
36.
Ma D, Zhu W, Hu S, et al: Association between oxidative stress and telomere length in type 1 and type 2 diabetic patients. J Endocrinol Invest 2013; 36:1032–1037
37.
Schwarzschild MA, Ascherio A, Beal MF, et al: Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014; 71:141–150
38.
Nakajima H, Unoda K, Ito T, et al: The relation of urinary 8-OHdG, a marker of oxidative stress to DNA, and clinical outcomes for ischemic stroke. Open Neurol J 2012; 6:51–57
39.
Noonan K, Carey LM, Crewther SG: Meta-analyses indicate associations between neuroendocrine activation, deactivation in neurotrophic and neuroimaging markers in depression after stroke. J Stroke Cerebrovasc Dis 2013; 22:e124–e135
40.
Launois SH, Pépin JL, Lévy P: Sleep apnea in the elderly: a specific entity? Sleep Med Rev 2007; 11:87–97
41.
Lavie P, Herer P, Peled R, et al: Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep 1995; 18:149–157
42.
Chen CY, Chen CL, Yu CC, et al: Association of inflammation and oxidative stress with obstructive sleep apnea in ischemic stroke patients. Sleep Med 2015; 16:113–118
43.
Farner L, Wagle J, Engedal K, et al: Depressive symptoms in stroke patients: a 13 month follow-up study of patients referred to a rehabilitation unit. J Affect Disord 2010; 127:211–218
44.
De Ryck A, Brouns R, Geurden M, et al: Risk factors for poststroke depression: identification of inconsistencies based on a systematic review. J Geriatr Psychiatry Neurol 2014; 27:147–158
Information & Authors
Information
Published In
History
Received: 31 May 2017
Revision received: 31 August 2017
Accepted: 19 September 2017
Published online: 25 January 2018
Published in print: Spring 2018
Keywords
Authors
Funding Information
Chang Gung Medical Research Council: CMRPG2E0013, 3B1441
Supported by the Chang Gung Medical Research Council (contract CMRPG2E0013, 3B1441).The authors report no financial relationships with commercial interests.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).